Author
@BPharmCatalyst BPharmCatalyst
High-volume biotech catalyst news feed: FDA, trial readouts, M&A, financings, all tickered.
Aggregate and relay real-time clinical-stage biopharma event
trader score
·
hit rate
·
mean α
·
signals 14d
42
Grade = how their written analysis reads (A best). Trader score = how their last-20 timestamped calls performed vs SPY.
Their picks, scored
Not yet in the scored-bets universe (fewer than 20 scoreable calls). Their last-14d mentions, direction-adjusted, have moved -4.9% since posting (mean over 21 mentions with price data).
Recent signals15receipts included
| date (PT) | ticker | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|---|
| 2026-10-16 | IRD | @BPharmCatalyst | +0.50 | IRD announces FDA approval of its supplemental application for phentolamine treating presbyopia. | · | tweet ↗ |
| 2026-10-16 | PYPD | @BPharmCatalyst | +0.00 | Publishes a biotech watchlist for catalysts expected in mid-winter 2026. | · | tweet ↗ |
| 2026-10-16 | NTLA | @BPharmCatalyst | +0.00 | Publishes a biotech watchlist for catalysts expected in mid-winter 2026. | -1.8% | tweet ↗ |
| 2026-10-16 | SVRA | @BPharmCatalyst | +0.00 | Publishes a biotech watchlist for catalysts expected in mid-winter 2026. | · | tweet ↗ |
| 2026-10-16 | INO | @BPharmCatalyst | +0.00 | Publishes a biotech watchlist for catalysts expected in mid-winter 2026. | -9.4% | tweet ↗ |
| 2026-10-16 | CAPR | @BPharmCatalyst | +0.00 | Publishes a biotech watchlist for catalysts expected in mid-winter 2026. | -11.6% | tweet ↗ |
| 2026-10-16 | VNDA | @BPharmCatalyst | +0.00 | Publishes a biotech watchlist for catalysts expected in mid-winter 2026. | -0.5% | tweet ↗ |
| 2026-10-16 | GUTS | @BPharmCatalyst | +0.65 | Revita meets its six-month pivotal-trial endpoint with statistically significant retention results. | · | tweet ↗ |
| 2026-10-15 | ESLA | @BPharmCatalyst | +0.20 | ESLA adds a fifth Phase 1/2 trial site, expanding recruitment capacity for STARLIGHT-1. | · | tweet ↗ |
| 2026-10-15 | SPRC | @BPharmCatalyst | -0.10 | SPRC announces an AI pivot but has no acquisitions, agreements or revenue supporting it yet. | -45.5% | tweet ↗ |
| 2026-10-14 | VNDA | @BPharmCatalyst | -0.65 | VNDA reports that its Phase 3 VQW-765 program failed to meet the primary endpoint. | -5.0% | tweet ↗ |
| 2026-10-14 | CDT | @BPharmCatalyst | +0.25 | CDT portfolio company Sarborg files a patent and prepares testing and partnering work. | · | tweet ↗ |
| 2026-10-14 | SVRA | @BPharmCatalyst | +0.00 | Flags three biotech companies with potentially market-moving FDA decisions due in November. | · | tweet ↗ |
| 2026-10-14 | SMMT | @BPharmCatalyst | +0.00 | Flags three biotech companies with potentially market-moving FDA decisions due in November. | +2.2% | tweet ↗ |
| 2026-10-14 | CAPR | @BPharmCatalyst | +0.00 | Flags three biotech companies with potentially market-moving FDA decisions due in November. | -10.0% | tweet ↗ |
Grade is our human read-worthiness rating; trader score is a rolling 20-bet hit-rate/alpha composite — different things, often disagreeing. “Since then” is direction-unaware in the table; the summary line above adjusts for which way they leaned.